Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONSTATRE
2004-000870-29Phase 4Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of risperidone in schizophrenia and schizoaffective disorder (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Time to relapse. Started Sep 2004; status: completed.
02
Drugs
risperidone
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on 2004-000870-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000870-29.